Purpose The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with nivolumab in participants with locally advanced or metastatic solid tumors. The study will consist of 2 parts: ABBV-368 dose escalation and ABBV-368 tumor-specific dose expansion (non-small cell lung cancer [NSCLC] cohort and head and neck cancer cohort) .
Mesothelioma
Atezolizumab and Bevacizumab in Rare Solid Tumors
Purpose: The goal of this clinical research study is to learn if atezolizumab and bevacizumab can help to control rare solid tumors.
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Purpose: The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and gastric cancer.
Trial of Adcetris in CD30+ Malignant Mesothelioma
Purpose: The goal of this clinical research study is to learn if Adcetris (brentuximab vedotin) can help to control mesothelioma. The safety of this drug will also be studied.
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Purpose The NCI Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. In this protocol, we are modifying the patient s white blood cells with a retrovirus that has the gene for anti-mesothelin incorporated in the retrovirus.
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
Purpose: The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), and other B7-H3 expressing cancers. The study will also evaluate what is the highest dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with pembrolizumab.
A Study of ABBV-181 in Participants With Advanced Solid Tumors
Purpose: This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. The study will consist of 2 parts: ABBV-181 dose escalation and ABBV-181 dose expansion.
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Purpose: In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.
Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies
Purpose: Primary Objective: To establish the safety and tolerability of Selinexor when given in combination with standard chemotherapy regimens.
Secondary Objectives:To determine disease control and progression free survival of Selinexor administered with standard chemotherapy treatments.
Exploratory Objectives:To determine the correlation of translational biomarkers To compare serial assessment of mutation status in biopsies obtained at baseline and progression after clinical response to combination therapy
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Purpose: This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Skip to content